PROCEPT BioRobotics Corporation Financing Cash Flow
PROCEPT BioRobotics Corporation (PRCT) reported Financing Cash Flow of $4.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.50M, a 2.70% increase year-over-year.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $222.00K, a 82.90% decline year-over-year.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.44M, a 97.40% decline year-over-year.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.08M, a 37.20% decline year-over-year.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for fiscal 2025 was $11.19M, a 93.79% decline from fiscal 2024.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for fiscal 2024 was $180.13M, a 7.35% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for fiscal 2023 was $167.79M, a 4545.49% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation net cash provided by (used in) financing activities for fiscal 2022 was $3.61M, a 98.62% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.72M 10-Q · filed 2026-08-05 | $9.16M derived: sum of 3 quarters · filed 2026-08-05 | $10.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $222.00K 10-Q · filed 2026-04-30 | $4.66M derived: sum of 2 quarters · filed 2026-04-30 | $5.74M derived: sum of 3 quarters · filed 2026-04-30 | $10.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.52M derived: sum of 2 quarters · filed 2026-02-26 | $9.89M derived: sum of 3 quarters · filed 2026-08-05 | $11.19M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.46M derived: sum of 2 quarters · filed 2026-08-05 | $6.75M 10-Q · filed 2025-11-05 | $177.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.68M 10-Q · filed 2026-08-05 | $176.20M derived: sum of 3 quarters · filed 2026-08-05 | $177.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.30M 10-Q · filed 2026-04-30 | $171.83M derived: sum of 2 quarters · filed 2026-04-30 | $173.54M derived: sum of 3 quarters · filed 2026-04-30 | $178.84M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $170.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $172.24M derived: sum of 2 quarters · filed 2026-02-26 | $177.54M derived: sum of 3 quarters · filed 2026-02-26 | $180.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.01M derived: sum of 2 quarters · filed 2025-11-05 | $9.60M 10-Q · filed 2025-11-05 | $12.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $7.88M 10-Q · filed 2025-08-07 | $10.75M derived: sum of 3 quarters · filed 2026-02-26 | $172.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.59M 10-Q · filed 2025-05-02 | $5.45M derived: sum of 2 quarters · filed 2026-02-26 | $167.57M derived: sum of 3 quarters · filed 2026-02-26 | $170.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $164.99M derived: sum of 2 quarters · filed 2026-02-26 | $167.41M derived: sum of 3 quarters · filed 2026-02-26 | $167.79M 10-K · filed 2026-02-26 |
| 2023-09-30 | $162.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-28 | $164.55M derived: sum of 2 quarters · filed 2024-10-28 | $164.93M 10-Q · filed 2024-10-28 | $163.61M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $2.81M 10-Q · filed 2024-08-02 | $1.49M derived: sum of 3 quarters · filed 2025-02-27 | $2.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $380.00K 10-Q · filed 2024-05-02 | -$938.00K derived: sum of 2 quarters · filed 2025-02-27 | -$161.00K derived: sum of 3 quarters · filed 2025-02-27 | $2.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$541.00K derived: sum of 2 quarters · filed 2025-02-27 | $2.32M derived: sum of 3 quarters · filed 2025-02-27 | $3.61M 10-K · filed 2025-02-27 |
| 2022-09-30 | $777.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.64M derived: sum of 2 quarters · filed 2023-11-02 | $4.93M 10-Q · filed 2023-11-02 | $5.57M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $4.15M 10-Q · filed 2023-07-28 | $4.80M derived: sum of 3 quarters · filed 2024-02-28 | $178.92M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.29M 10-Q · filed 2023-05-04 | $1.94M derived: sum of 2 quarters · filed 2024-02-28 | $176.06M derived: sum of 3 quarters · filed 2024-02-28 | $262.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $644.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $174.77M derived: sum of 2 quarters · filed 2024-02-28 | $260.89M derived: sum of 3 quarters · filed 2024-02-28 | $262.12M 10-K · filed 2024-02-28 |
| 2021-09-30 | $174.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $260.25M derived: sum of 2 quarters · filed 2022-11-04 | $261.47M 10-Q · filed 2022-11-04 | $261.71M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $86.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $87.35M 10-Q · filed 2022-08-05 | $87.59M derived: sum of 3 quarters · filed 2022-08-05 | |
| 2021-03-31 | $1.23M 10-Q · filed 2022-05-06 | $1.46M derived: sum of 2 quarters · filed 2022-05-06 | ||
| 2020-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $106.77M 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $106.53M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |